-
公开(公告)号:AT496032T
公开(公告)日:2011-02-15
申请号:AT03026298
申请日:2000-02-15
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , BRANCA QUIRICO , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07D213/82 , A61K20060101 , A61K31/44 , A61K31/4409 , A61K31/4418 , A61K31/4427 , A61K31/444 , A61K31/455 , A61K31/496 , A61P1/00 , A61P9/00 , A61P11/00 , A61P25/00 , A61P25/04 , A61P25/28 , A61P25/30 , A61P27/02 , A61P29/00 , A61P43/00 , C07D20060101 , C07D213/30 , C07D213/38 , C07D213/40 , C07D213/63 , C07D213/65 , C07D213/74 , C07D213/75 , C07D213/78 , C07D401/04 , C07D401/12 , C07D413/12 , C07D413/14
Abstract: The present invention relates to compounds of the general formula wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R is hydrogen or halogen; or R and R may be together -CH=CH-CH=CH-; R and R are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R and R may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R is hydrogen, lower alkyl or form a cycloalkyl group; R is hydrogen, -N(R )2, -N(R )(CH2)nOH, -N(R )S(O)2-lower alkyl, -N(R )S(O)2-phenyl, -N=CH-N(R )2, -N(R )C(O)R or a cyclic tertiary amine of the group R is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl; R is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R )CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R )-, -(CH2)mO-, -(CH2)mN(R )-, -N(R )C(O)-, or -N(R )(CH2)m-; n is 0 - 4; and m is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK-1 receptor. They may be used for the treatment of diseases, which relate to NK-1 receptor antagonists.
-
公开(公告)号:DE60131971T2
公开(公告)日:2008-12-04
申请号:DE60131971
申请日:2001-06-01
Applicant: HOFFMANN LA ROCHE
Inventor: GALLEY GUIDO , GODEL THIERRY , GOERGLER ANNICK , HOFFMANN TORSTEN , KOLCZEWSKI SABINE , ROEVER STEPHAN
IPC: C07D471/10 , A61K31/437 , A61K31/445 , A61P1/04 , A61P9/00 , A61P11/00 , A61P11/06 , A61P25/06 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P37/08 , A61P43/00
Abstract: The invention relates to compounds of the formulaas described herein and pharmaceutically acceptable acid addition salts thereof. The described compounds have a good affinity to the NK1 receptor.
-
公开(公告)号:GC0000338A
公开(公告)日:2007-03-31
申请号:GCP2000685
申请日:2000-05-30
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K31/00 , A61K31/505 , A61K31/506 , A61K31/513 , A61K31/5377 , A61P1/04 , A61P1/08 , A61P9/00 , A61P11/02 , A61P11/06 , A61P17/02 , A61P25/00 , A61P25/06 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/30 , A61P29/00 , A61P37/08 , A61P43/00 , C07D213/00 , C07D239/00 , C07D239/28 , C07D239/34 , C07D239/38 , C07D239/42 , C07D239/46 , C07D239/48 , C07D295/00 , C07D401/04
Abstract: Compounds of the general formula are described:whereinR is hydrogen or halogen;R is hydrogen, halogen, lower alkyl or lower alkoxy;R is halogen, trifluoromethyl, lower alkoxy or lower alkyl;R /R are each independently hydrogen or lower alkyl;R is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, -(CH2)n-piperazinyl, optionally substituted by lower alkyl, -(CH2)n-morpholinyl, -(CH2)n+1-imidazolyl, -O-(CH2)n+1-morpholinyl, -O-(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, -NH-(CH2)n+1N(R )2, -(CH2)n-NH-(CH2)n+1N(R )2, -(CH2)n+1N(R )2, or -O-(CH2)n+1N(R )2, wherein R is hydrogen or lower alkyl;R is hydrogen;R and R or R and R may together be -CH=CH-CH=CH-, wherein R and R or R and R , respectively, together with the two carbon ring atoms to which they are attached form a fused ring, with the proviso that n for R is 1;n is independently 0-2; andX is -C(O)N(R )- or -N(R )C(O)-;and pharmaceutically acceptable acid addition salts thereof.
-
公开(公告)号:AT353881T
公开(公告)日:2007-03-15
申请号:AT01960225
申请日:2001-05-18
Applicant: HOFFMANN LA ROCHE
Inventor: GALLEY GUIDO , GOERGLER ANNICK , GODEL THIERRY , HECK REINHARD
IPC: C07D243/08 , A61K31/551 , A61K31/5517 , A61P1/04 , A61P1/08 , A61P9/00 , A61P11/06 , A61P13/10 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/06 , A61P27/02 , A61P29/00 , A61P37/08 , C07D243/14 , C07D401/06 , C07D401/14 , C07D403/06 , C07D409/06 , C07D487/04
Abstract: The invention relates to compounds of the formulawhereinR1, R2 are independently from each other aryl or heteroaryl, wherein the heteroaryl group contains one or two heteroatoms, selected from N, O, or S, and wherein the aryl or heteroaryl groups are optionally substituted by 1 to 3 substituents, which are independently from each other halogen, CF3, lower alkoxy or lower alkyl;R3 is hydrogen, lower alkyl, -(CH2)nN(R)2, -(CH2)n-heteroaryl or is a -(CH2)n-non aromatic heterocycle, which heterocycles are optionally substituted by halogen, CF3, lower alkoxy or lower alkyl;R4 is =O, =N(CH2)nCH3 or =N(CH2)nN(R)2;R3 and R4 may be together with the N and C atoms to which they are attached the group -CR5=N-N=; R5 is hydrogen, -(CH2)nN(R)2, -(CH2)n-heteroaryl or is a -(CH2)n-non aromatic heterocycle, which heterocycles are optionally substituted by halogen, CF3, lower alkoxy or lower alkyl;R is hydrogen or lower alkyl;n is 0, 1, 2 or 3;and pharmaceutically acceptable acid addition salts and enantiomeric forms thereof. The compounds are useful in the treatment of diseases, related to the NK-1 receptor.
-
公开(公告)号:DE60031513D1
公开(公告)日:2006-12-07
申请号:DE60031513
申请日:2000-02-15
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07C211/44 , C07D213/75 , A61K31/167 , A61K31/44 , A61P25/00 , A61P29/00 , C07C211/54 , C07C233/29 , C07C233/33 , C07C233/44 , C07C317/14 , C07C317/40 , C07C323/41 , C07D213/79 , C07D213/81 , C07D295/12 , C07D295/135 , C07D401/04
Abstract: The present invention is a series of compounds formed from phenyl substituted pyridine or benzene derivatives and their pharmaceutically acceptable salts. These compounds have shown high affinity as antagonists to the NK-1 receptor.
-
公开(公告)号:DE60120419D1
公开(公告)日:2006-07-20
申请号:DE60120419
申请日:2001-07-27
Applicant: HOFFMANN LA ROCHE
Inventor: GODEL THIERRY , HOFFMANN TORSTEN , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07D213/74 , A61K31/44 , A61K31/4427 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/455 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/06 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P29/02 , A61P37/00 , A61P37/08 , A61P43/00 , C07D213/75 , C07D213/79 , C07D213/82 , C07D401/04 , C07D401/06 , C07D401/12 , C07D409/04 , C07D413/04 , C07D417/04 , C07D521/00
Abstract: Substituted 4-phenyl-pyridine compounds with activity as antagonists of Neurokinin 1 receptors, methods of making these compounds and preparing.
-
公开(公告)号:SI1187815T1
公开(公告)日:2006-06-30
申请号:SI200030813
申请日:2000-05-24
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: C07D239/00 , A61K31/00 , A61K31/496 , A61K31/505 , A61K31/506 , A61K31/5377 , A61P1/04 , A61P1/08 , A61P9/00 , A61P11/06 , A61P17/02 , A61P19/02 , A61P25/00 , A61P25/06 , A61P25/16 , A61P25/22 , A61P25/24 , A61P25/28 , A61P25/36 , A61P27/00 , A61P27/02 , A61P29/00 , A61P37/08 , A61P43/00 , C07D213/00 , C07D239/28 , C07D239/32 , C07D239/34 , C07D239/38 , C07D239/42 , C07D239/48 , C07D295/00 , C07D401/00 , C07D401/04 , C07D403/04
-
公开(公告)号:YU8703A
公开(公告)日:2006-05-25
申请号:YUP8703
申请日:2001-07-27
Applicant: HOFFMANN LA ROCHE
Inventor: GODEL THIERRY , HOFFMANN TORSTEN , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K31/44 , A61K31/4427 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/455 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P11/00 , A61P17/02 , A61P25/00 , A61P25/06 , A61P25/28 , A61P25/36 , A61P27/02 , A61P27/16 , A61P29/00 , A61P29/02 , A61P37/00 , A61P37/08 , A61P43/00 , C07D213/74 , C07D213/75 , C07D213/79 , C07D213/82 , C07D401/04 , C07D401/06 , C07D401/12 , C07D409/04 , C07D413/04 , C07D417/04 , C07D521/00
Abstract: Ovaj pronalazak se odnosi na jedinjenja opšte formule (I) u kojoj R označava vodonik ili halogen, R i R2 ili R4 i R4 mogu zajedno biti -CH=CH-CH=CH- koji je opciono supstituisan sa jednim ili dva supstituenta koji su odabrani izmedju nižeg alkila, halogena ili nižeg alkoksi, X označava -C(O)N(R8)-, -(CH2)pO-, -(CH2)pN(R8)-, -N(R8)C(O)- ili -N(R8)-(CH2)p- pri čemu R8 označava vodonik ili niži alkil, n je 1 ili 2, m je 0, 1, 2, 3 ili 4, O je 1 ili 2 i p je 1 ili 2, i na njihove farmaceutski prihvatljive kiselinske adicione soli. Nadjeno je da su jedinjenja data ovim pronalaskom antagonisti receptora Neurokinina 1 (NK-1, supstance P) i otuda su prikladna (primenljiva) u terapiji bolesti koje su u vezi sa ovim receptorom.[The present invention relates to compounds of the general formula (I) wherein a.o. 5 R is hydrogen or halogen; R and R2 or R4 and R4' may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl, halogen or lower alkoxy; X is -C(O)N(R8)-, (CH2)pO-, -(CH2)pN(R8)-, -N(R8)C(O)- or -N(R8)-(CH2)p-; wherein R8 is hydrogen or lower alkyl; n is 1 or 2; m is 0, 1, 2, 3, or 4; O is 1 or 2; and p is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. It has been found that the compounds of the present invention are antagonists of the Neurokinin 1 (NK-1, substance P) receptor, and they are therefore useful in the treatment of diseases, related to this receptor.
-
公开(公告)号:GC0000183A
公开(公告)日:2006-03-29
申请号:GCP2000535
申请日:2000-02-23
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K31/44 , A61P25/00 , A61P29/00 , C07D213/30 , C07D213/38 , C07D213/75 , C07D213/81 , C07D401/04
Abstract: The invention relates to compounds of the formulawhereinR is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;R1 is hydrogen or halogen; orR and R1 may be together -CH=CH-CH=CH-;R2 is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano;R3 is hydrogen, lower alkyl or form a cycloalkyl group;R4 is hydrogen, -N(R5)2, -N(R5)S(O)2-lower alkyl, -N(R5)C(O)R5 or a cyclic tertiary amine of the groupR5 is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl;R6 is hydrogen, hydroxy, lower alkyl, -N(R5)CO-lower alkyl, hydroxy-lower alkyl, cyano, -CHO or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group,X is -C(O)N(R5)-, -(CH2)mO-, -(CH2)mN(R5)-, -N(R5)C(O)-, or -N(R5)(CH2)m-;n is 0-4; andm is 1 or 2;and to pharmaceutically acceptable acid addition salts thereof.It has been shown that the above mentioned compounds have a good affinity to the NK-1 receptor.
-
公开(公告)号:DE60015089T2
公开(公告)日:2006-02-16
申请号:DE60015089
申请日:2000-02-15
Applicant: HOFFMANN LA ROCHE
Inventor: BOES MICHAEL , GALLEY GUIDO , GODEL THIERRY , HOFFMANN TORSTEN , HUNKELER WALTER , SCHNIDER PATRICK , STADLER HEINZ
IPC: A61K31/44 , A61P25/00 , A61P29/00 , C07D213/30 , C07D213/38 , C07D213/75 , C07D213/81 , C07D401/04
Abstract: The invention relates to compounds of the formulawhereinR is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;R1 is hydrogen or halogen; orR and R1 may be together -CH=CH-CH=CH-;R2 is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano;R3 is hydrogen, lower alkyl or form a cycloalkyl group;R4 is hydrogen, -N(R5)2, -N(R5)S(O)2-lower alkyl, -N(R5)C(O)R5 or a cyclic tertiary amine of the groupR5 is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl;R6 is hydrogen, hydroxy, lower alkyl, -N(R5)CO-lower alkyl, hydroxy-lower alkyl, cyano, -CHO or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group,X is -C(O)N(R5)-, -(CH2)mO-, -(CH2)mN(R5)-, -N(R5)C(O)-, or -N(R5)(CH2)m-;n is 0-4; andm is 1 or 2;and to pharmaceutically acceptable acid addition salts thereof.It has been shown that the above mentioned compounds have a good affinity to the NK-1 receptor.
-
-
-
-
-
-
-
-
-